Literature DB >> 15641694

Experimental study on induction of renal cell carcinoma apoptosis by antisense oligonucleotide targeting survivin.

Jian Peng1, Zhangqun Ye, Tao Zheng, Li Ruan.   

Abstract

The effect of antisense oligonucleotide (ASODN) targeting survivin on renal cell carcinoma (RCC) apoptosis, proliferation and sensitivity to chemotherapeutic drugs was investigated. Antisense oligonucleotide targeting survivin was designed and composed. The cDNA of survivin was transfected into RCC cell lines ACHN and 769-P, respectively. They were both cultured in normal condition. After transfection, ACHN and 769-P cell lines were cultured in a 6-well culture plate. The cultured cells were divided into 6 groups. Twenty-four h after transfection, survivin protein expression was detected by Western blot. Apoptotic index (AI) and proliferative index (PI) were examined by flow cytometry. Rate of inhibition (IR) by chemotherapeutic drugs was determined by the colorimetric MTT cell viability/proliferation assay. The results showed AI and IR of chemotherapeutic drugs in ASODN groups were significantly higher than those in the groups without ASODN. There were statistical differences between ASODN groups and control groups (P< 0.05), but there was no difference among control groups (P>0.05). The PI in the ASODN groups was significantly lower than that in the control groups with the difference being statistically significant (P<0.05). In addition, there were no differences among control groups. It was concluded that the expression of survivin could be down-regulated in 2 cell lines after ASODN transfection. Antisense oligonucleotide targeting survivin could induce RCC apoptosis, inhibit cell proliferation and sensitize RCC to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15641694     DOI: 10.1007/BF02831110

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

1.  Structural biology. Controlling the caspases.

Authors:  S W Fesik; Y Shi
Journal:  Science       Date:  2001-11-16       Impact factor: 47.728

Review 2.  The Survivin saga goes in vivo.

Authors:  J C Reed
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

3.  A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.

Authors:  R A Olie; A P Simões-Wüst; B Baumann; S H Leech; D Fabbro; R A Stahel; U Zangemeister-Wittke
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

Review 4.  Antiapoptotic proteins. The bcl-2 and inhibitor of apoptosis protein families.

Authors:  Q L Deveraux; S L Schendel; J C Reed
Journal:  Cardiol Clin       Date:  2001-02       Impact factor: 2.213

Review 5.  Antisense oligonucleotides: promise and reality.

Authors:  I Lebedeva; C A Stein
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

6.  Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation.

Authors:  A Suzuki; M Hayashida; T Ito; H Kawano; T Nakano; M Miura; K Akahane; K Shiraki
Journal:  Oncogene       Date:  2000-07-06       Impact factor: 9.867

7.  Cancer gene therapy using a survivin mutant adenovirus.

Authors:  M Mesri; N R Wall; J Li; R W Kim; D C Altieri
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 8.  Mechanisms of caspase activation and inhibition during apoptosis.

Authors:  Yigong Shi
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

9.  Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53.

Authors:  D Grossman; P J Kim; O P Blanc-Brude; D E Brash; S Tognin; P C Marchisio; D C Altieri
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 10.  Survivin apoptosis: an interloper between cell death and cell proliferation in cancer.

Authors:  D C Altieri; P C Marchisio; C Marchisio
Journal:  Lab Invest       Date:  1999-11       Impact factor: 5.662

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.